Since we aim to utilize ITF3756 as a therapeutic compound for cancer treatment, we investigated whether ITF3756 exerts the same modulatory effect on PD-L1 expression in monocytes from cancer patients as it does in monocytes collected from healthy donors. The gene discussed is CD274; the disease is cancer.